Evidence map›Paper›PMID 38073638›Full record

ReviewFrontiers in neurology2023

Advances in neuroproteomics for neurotrauma: unraveling insights for personalized medicine and future prospects.

Firas Kobeissy, Mona Goli, Hamad Yadikar, Zaynab Shakkour, Milin Kurup, Muhammad Ali Haidar, Shahad Alroumi, Stefania Mondello, Kevin K Wang, Yehia Mechref

Abstract readReview
In one paragraph

Review in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Firas Kobeissy *Department of Neurobiology, School of Medicine, Neuroscience Institute, Atlanta, GA, United States.
Mona Goli *Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX, United States.
Hamad Yadikar *Department of Biological Sciences Faculty of Science, Kuwait University, Safat, Kuwait.
Zaynab ShakkourDepartment of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia, MO, United States.
Milin KurupAlabama College of Osteopathic Medicine, Dothan, AL, United States.
Muhammad Ali HaidarDivision of Neurobiology, Free University of Berlin, Berlin, Germany.
Shahad AlroumiDepartment of Biological Sciences Faculty of Science, Kuwait University, Safat, Kuwait.
Stefania MondelloDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
Kevin K WangDepartment of Neurobiology, School of Medicine, Neuroscience Institute, Atlanta, GA, United States.
Yehia MechrefDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX, United States.

Funding

Quantitative Characterization of Glycopeptide IsomersR01GM130091 · NIGMS · TEXAS TECH UNIVERSITY · PI Yehia Mechref · 2019 to 2026
$2.5M
NIGMS NIH HHS R01 GM130091
6 · The paper itself

Abstract

Neuroproteomics, an emerging field at the intersection of neuroscience and proteomics, has garnered significant attention in the context of neurotrauma research. Neuroproteomics involves the quantitative and qualitative analysis of nervous system components, essential for understanding the dynamic events involved in the vast areas of neuroscience, including, but not limited to, neuropsychiatric disorders, neurodegenerative disorders, mental illness, traumatic brain injury, chronic traumatic encephalopathy, and other neurodegenerative diseases. With advancements in mass spectrometry coupled with bioinformatics and systems biology, neuroproteomics has led to the development of innovative techniques such as microproteomics, single-cell proteomics, and imaging mass spectrometry, which have significantly impacted neuronal biomarker research. By analyzing the complex protein interactions and alterations that occur in the injured brain, neuroproteomics provides valuable insights into the pathophysiological mechanisms underlying neurotrauma. This review explores how such insights can be harnessed to advance personalized medicine (PM) approaches, tailoring treatments based on individual patient profiles. Additionally, we highlight the potential future prospects of neuroproteomics, such as identifying novel biomarkers and developing targeted therapies by employing artificial intelligence (AI) and machine learning (ML). By shedding light on neurotrauma's current state and future directions, this review aims to stimulate further research and collaboration in this promising and transformative field.

Indexed as

artificial intelligence (AI)machine learning (ML)neuroproteomicsneurotraumapersonalized medicine (PM)proteomicstraumatic brain injuries (TBI)

Identifiers

PMID38073638
PMCPMC10703396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.